Form 4: Genprex Director William R. Wilson Jr. Reports Acquisition of Restricted Stock Units

Genprex director William R. Wilson Jr. acquired 4,750 restricted stock units (RSUs) and now holds 7,845 shares following a recent transaction.

Summary

• Director William R. Wilson Jr. of Genprex, Inc. reported acquiring 4,750 restricted stock units (RSUs) on December 5, 2024.
• These RSUs were granted under the company's 2018 Equity Incentive Plan.
• The RSUs will vest 100% on the earlier of June 30, 2025, or the day before the next annual meeting of stockholders, provided Mr. Wilson remains a service provider.
• Vested RSUs will be paid in shares of Genprex common stock on a one-to-one basis.
• Following this transaction, Mr. Wilson beneficially owns 7,845 shares of Genprex common stock.
• This total includes adjustments for the 1-for-40 reverse stock split that occurred on February 2, 2024.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of a director receiving RSUs, which is generally positive as it aligns interests with the company's success. There are no indications of negative sentiment.

Positives

• The acquisition of RSUs by a director indicates confidence in the company's future performance.
• The vesting schedule aligns the director's interests with the company's long-term success.

Risks

• The vesting of the RSUs is contingent on Mr. Wilson remaining a service provider, which introduces a risk of forfeiture if he leaves the company before the vesting date.

Future Outlook

The RSUs will vest on the earlier of June 30, 2025, or the day before the next annual meeting of stockholders, provided Mr. Wilson remains a service provider.

Industry Context

This is a standard transaction for a director of a publicly traded company, often used as part of compensation and to align interests with shareholders.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as part of director compensation is a common practice in the biotechnology industry, similar to companies like Amgen and Gilead Sciences.
• The vesting schedule, tied to continued service and a future date or event, is also a standard approach to incentivize long-term commitment, comparable to practices at companies like Regeneron and Biogen.
• The 1-for-40 reverse stock split is a measure often taken by companies to increase their share price and maintain listing requirements, similar to actions taken by other small-cap biotech firms.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's long-term performance.

Next Steps

• The RSUs will vest on the earlier of June 30, 2025, or the day before the next annual meeting of stockholders, provided Mr. Wilson remains a service provider.

Key Dates

Keywords

Genprex, Restricted Stock Units, RSUs, Director, Beneficial Ownership, Equity Incentive Plan, Stock Split, Form 4